Related Topics:
Facility ID: 9050WPLYPP365MA
Facility Name and Address: POLYPEPTIDE LABORATORIES INC. 365 MAPLE AVE TORRANCE, CA 90503 Parent Company: POLYPEPTIDE LABORATORIES INC Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: N,N-Dimethylformamide Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0000068122
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2022 |
Source Reduction:: S21: Optimized process conditions to increase efficiency
|
Methods to Identify SR Opportunities: T04: Participative team management
|
|
2021 |
Source Reduction:: S21: Optimized process conditions to increase efficiency
|
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
Methods to Identify SR Opportunities: T04: Participative team management |
S21: PolyPeptide has an active ongoing program to optimize the utilization of Dimethylformamide. |
2020 |
Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
|
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
Methods to Identify SR Opportunities: T04: Participative team management |
|
2019 |
Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
|
Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s) |
W50: Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%. Source Reduction - Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%. |
2018 |
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.
|
Barriers to P2: B5 - Specific regulatory/permit burdens. - FDA approved production process. Changes must be approved by FDA. |
|
2016 |
Source Reduction:: W32: Improved procedures for loading, unloading, and transfer operations
|
Methods to Identify SR Opportunities: T10: Vendor assistance
|
|
2015 |
Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis[-0-4%]
|
Methods to Identify SR Opportunities: T04: Participative team management
|
Source Reduction - Our clients are changing their BOC chemistry to FMOC chemistry where possible at the outset of drug development which can reduce certain hazardous reactants with less hazardous reactants.. |
2014 |
Source Reduction:: W15: Introduced an in-line product quality monitoring or other process analysis system
|
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
|
|
2013 |
Source Reduction:: W19: Other changes in operating practices
|
Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T06: Employee recommendation (under a formal company program) Methods to Identify SR Opportunities: T11: Other |
W19: The company is utilizing lean manufacturing principles. Source Reduction - Continuous improvement is encouraged in all work procedures. Source Reduction - Daily production scheduling meetings are held to address immediate concerns in addition to weekly project meetings which are held to plan longer term projects and actions. Barriers to P2 - Recycling statements for TRI section 8.11Polypeptide Laboratories produces customized Polypeptides for drug formulation for major pharmaceutical corporations. Each formulation requires pure reagents, thus no recycling can be attempted for reagents. |
2012 |
Source Reduction:: W19: Other changes in operating practices
|
Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T06: Employee recommendation (under a formal company program) Methods to Identify SR Opportunities: T11: Other |
W19: Implementation of lean manufacturing to optimize operation cost and bottle necks in production workflow Source Reduction - Continuous improvement Source Reduction - Suggestions on increasing production efficiency Source Reduction - Internal meeting to optimize operation costs, reduce waste and costs |